This SBIR Phase I project will employ a new bioinformatic tool to combine in silico gene mapping and comparative genomics for predicting designer rat strains that mimic human disease. The genome sequencing projects are bringing new molecular tools to both the pharmacologist and toxicologist. … More

This SBIR Phase I project will create and validate a combinatorial panel of rats designed to detect genetic differences to drug response including toxicity. The genome sequencing projects are bringing new molecular tools to both the pharmacologist and toxicologist. However, each species has its own… More

DESCRIPTION (provided by applicant): The recent anthrax-related events have revealed the need to fill gaps in the knowledge base that compromise our response to a bioterrorist attack using Category A pathogens like Bacillus anthracis. As with most biological systems, there is tremendous diversity… More

DESCRIPTION (provided by applicant): The concept of a pre-clinical, drug screen for genetic effects was developed by PhysioGenix in Phase I of this project. The screen consists of inbred rats bred in a combinatorial fashion such that F1 offspring mimic the genetically diverse human population, while… More

DESCRIPTION (provided by applicant): This Phase I SBIR project uses a new Quality Control microarray (QCarray) technology to generate Drug Toxicity Signatures (DTSs) for predicting liver toxicity in rat. The QCarray enables each element on every array to have a quality control (QC) score and… More

DESCRIPTION (provided by applicant): PhysioGenix plans to commercialize a rat discovery platform that markedly accelerates the deployment of genetic tools for drug development by Pharma. While genetics can offer pharmaceutical companies a powerful discovery tool, this strategy has not been widely… More

DESCRIPTION (provided by applicant): This SBIR project combines the use of genetic models with genomic, proteomic and metabolomic technologies as a solution to discover molecular fingerprints as biomarkers for alcohol-induced organ damage. While several classic biomarkers have been used by… More

Not avaiable.

DESCRIPTION (provided by applicant): The number of patients in the United States afflicted with learning and memory disorders is rapidly increasing. This necessitates the development of new, better acting and safer medications for enhancing cognition. In this SBIR Phase I project, PhysioGenix will… More